When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Transcript (slightly modified)
I like to tell audiences that what worries me the most is we have Star Wars science and innovation, and we have Flintstones delivery. I think we’re really trying hard to be able to have the delivery system catch up to the innovation. I believe that people in health policy tend to care more about healthcare cost and healthcare cost growth than understanding what the potential impact might be on individual and population health if we deliver care in a more appropriate way. So, 1 is that I’m incredibly excited about the fact that now we can have therapies derived from an individual patient’s cells to treat their own cancers, understanding though that immediately the media is not about the clinical benefits which come with that, but the $450,000 price tag or the $1 million price tag, or the $2 million price tag.
So, understanding that we have to balance both clinical benefit and cost. We can’t give everything to everyone in all circumstances, and that’s where value-based insurance design comes in. I think that when a drug becomes first-line, whether it be immediately because you have such a targeted situation, or you’ve taken 2, 3, maybe even 4 lower cost drugs and now you end up in these high cost or precision therapies, it is my opinion as a clinician that when I deem a therapy to be first-line, which may be day 1 or day 1,000, and it may be therapy 1 or it may be therapy 6, but in that day when it is my first-line or the best therapy for the patient, I would like to think that I as a clinician would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them.
I understand that there’s great tension; I’m not sure that we’ll get the answer right away. But, the more we understand that there thankfully is a lot of waste in the system, that if we were to identify and remove some of that, would give us some headway moving forward to allow us to pay for innovation moving forward and not be in that crunch situation where a public or private payer says, “If you don’t give me a dollar back, in a hospitalization or ER visit avoided, I’m not going to approve this therapy for use.”
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More